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L&HCP Faculty Awarded NIH Grant to Study 
Regulation of Microbiota Transplantation
In June, Director of the L&HCP Diane Hoffmann, along with colleagues at 
the University of Maryland Schools of Law, Medicine, and Pharmacy, were 
awarded an NIH grant to study the legal and regulatory aspects of a cutting 
edge medical treatment called microbiota transplantation. Hoffmann will serve 
as Principal Investigator for the two-year grant, Microbiota Transplantation: 
Recommendations for a Regulatory Framework, that will look at options 
for regulating current and emerging uses of microbiota transplantation 
including fecal, vaginal, skin, anterior nares, oral, and whole body transplants.  
Collaborating with Hoffmann as Co-Investigators are: 
•	 Dr. Frank Palumbo, Center on Drugs and Public Policy, University of 
Maryland School of Pharmacy 
•	 Dr. Jacques Ravel, Institute for Genome Sciences, University of  
Maryland School of Medicine
•	 Dr. Mary-Claire Roghmann, Department of Epidemiology and Public 
Health, University of Maryland School of Medicine 
•	 Dr. Erik Von Rosenvinge, University of Maryland School of Medicine 
and Department of Gastroenterology, Veterans Affairs Maryland Health 
Care System 
•	 Virginia Rowthorn, Law & Health Care Program, University of 
Maryland Carey School of Law
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The project builds on Hoffmann’s prior NIH grant that assessed the 
regulatory framework for probiotics (or live microorganisms which when 
administered in adequate amounts confer a health benefit on the host) in 
the United States by convening a multidisciplinary Working Group to 
provide a critical review of current probiotic regulation.  From 2009 to 
2014, Hoffmann and her co-investigators studied how the Food and Drug 
Administration (FDA) should regulate probiotics under a grant funded by 
NIH’s Human Microbiome Project (HMP), a $150 million NIH initiative 
to characterize the microbial communities found at several different sites 
on the human body and to analyze the role of these microbes in human 
health and disease.  Until recently, the abundant community of human-
associated microbes (which outnumber human cells by about ten to one) 
was largely unstudied, leaving their influence upon human development, 
physiology, immunity, and nutrition almost entirely unknown. The HMP 
was established to support the comprehensive characterization of the 
human microbiota and analysis of their role in human health and disease.  
Advances in DNA sequencing technologies have created the field of 
metagenomics that allows analysis of genetic material harvested directly 
from microbial communities.  HMP scientists are using metagenomics 
and genetic analyses of available reference microbial strains to understand 
the complexity of human-associated microbial communities and how 
the microbiome and human host interact to support health or to trigger 
disease.  One of the most significant outgrowths of the HMP is advanced 
research into probiotics.
A portion of HMP funds was set aside to study the Ethical, Legal, and 
Social Implications (often referred to as the ELSI issues) of the HMP’s 
scientific goals and these early HMP grants were administered by the 
National Human Genome Research Institute (NHGRI).  Both Hoffmann’s 
2009 and 2015 awards were ELSI grants.  The first was awarded by 
NHGRI and the most recent by the National Institute of Allergy and 
Infectious Diseases.  Hoffmann's collaborators on the probiotic grant 
were Drs. Palumbo and Ravel (along with Dr. Claire Fraser, Professor and 
Director, Institute of Genome Sciences, University of Maryland School 
of Medicine, and Jack Schwartz, Adjunct Professor at University of 
Maryland Carey School of Law) which led to numerous publications and 
follow-on work (see box, page 6).  
In addition to the development of probiotic therapies, advances in 
our understanding of the human microbiome are also likely to make 
microbiota transplants – or transplantation of bacteria from a healthy 
individual to a patient recipient to cure or manage a health condition - 
increasingly common.  At present, there is much interest and evidence-
based support for one type of microbiota transplant: fecal microbiota 
transplantation (FMT).  FMT involves the transplantation of fecal 
material into a patient recipient to treat various severe intestinal 
disorders.  Interest in FMT is growing as strong evidence is emerging 
that FMT is effective in treating Clostridium difficile infection and may 
also be effective in treating other gastrointestinal conditions.  FMT has 
been discussed widely in Atlantic Magazine (“When Feces Is the Best 
Medicine”), the New Yorker (“The Excrement Experiment”), and the 
New York Times (“When Pills Fail, This, er, Option Provides a Cure”).
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FMT is most commonly performed via colonoscopy 
using fecal material that is typically donated by 
a relative or partner and tested in advance for 
bloodborne infectious agents.  There is growing 
interest in administering the treatment in pill form 
for patients who may not be able to tolerate another 
delivery system and to make the treatment more 
palatable from an aesthetic and procedural perspective. 
At least one stool bank has been created to collect 
stool samples from healthy, pre-screened individuals, 
process the donations, and sell the product to clinics 
and there appears to be growing interest in this type 
of venture.  Other researchers are working on a 
cocktail of gastrointestinal bacteria collected from 
healthy volunteers and grown in the lab (to mimic the 
microbiome) that can be delivered in pill form.  This 
has been referred to as “synthetic feces”.
FMT is raising new legal and regulatory questions 
for FDA.  At present, via draft guidance released 
in July 2013, FDA stated that it would exercise 
enforcement discretion allowing physicians to use 
FMT to treat Clostridium difficile infection in patients 
who have not responded to standard therapies without 
filing an investigational new drug (IND) application 
with the agency.  The enforcement discretion policy 
does not extend to other uses of FMT so that a 
physician wanting to use FMT for any other condition 
must file an IND.  The guidance notes that “FDA 
intends to exercise this discretion on an interim basis 
while the Agency further considers the matter.”  
Although FMT is the focus of much attention, 
emerging microbiota transplantation options 
include vaginal, skin, oral, and anterior nares 
transplantations.  A further cutting edge use of 
microbiota transplantation is "whole microbiome" 
transplantation pioneered by Dr. Maria Dominguez-
Bello in which babies born via Cesarean section are 
swabbed in material that is placed in the mother’s 
birth canal during birth, allowing for babies to be 
exposed to important bacteria present in the vaginal 
canal.  Dr. Dominguez-Bellow has speculated that lack 
of exposure to these microbiota might explain why 
C-section babies are at greater risk of developing Type 
1 diabetes, celiac disease, asthma or obesity.1  Use of 
these other microbiota transplantation options is still in 
its infancy and there has been little, if any, discussion 
in the literature as to their appropriate regulation.
Hoffmann’s project will provide a timely 
examination of the appropriate regulatory path for 
fecal and other types of microbiota transplantation.  
Using the same research method that Hoffmann and 
her collaborators used with their probiotics project, 
Hoffmann will convene approximately 25 expert 
stakeholders to form a Working Group that will 
collaborate over the course of three meetings to craft 
recommendations.  The invited stakeholders who will 
meet for the first time in Baltimore on December 3 and 
4 include scientists, clinicians, patient and professional 
association advocates, bioethicists, government 
regulators, academics, lawyers, and individuals from 
the biotechnology industries who have an interest 
in microbiota transplantation or expertise relevant 
to the proposed project.  The Working Group will 
evaluate alternative regulatory options for microbiota 
transplantation and consider which regulatory 
approach or approaches would work for these 
procedures in a way that meets specific criteria for 
regulatory effectiveness.  Regulatory frameworks that 
may be appropriate in whole or in part for microbiota 
transplantation include the frameworks for regulating 
biological products, blood and blood products, 
vascularized organs, human cells, tissues and cellular 
products.  The Working Group will also consider 
whether a hybrid or new regulatory scheme is best 
to ensure the safety, effectiveness, and accessibility 
of the procedures. The investigators will include a 
description of the Working Group process and the 
recommendations in a paper or series of papers.  
____________
1See interview with Dr. Dominguez-Bello regarding the preliminary 
results of her research that were presented at the 2014 conference of the 
American Society for Microbiology in Boston.  WBUR radio interview, 
June 25, 2014.  http://commonhealth.wbur.org/2014/06/birth-canal-
bacteria-c-section
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NIH Microbiota Transplantation Grant
The Microbiota Research Team
Dr. Frank Palumbo
Frank Palumbo, 
Ph.D., JD, is a 
professor at the 
University of 
Maryland School 
of Pharmacy and 
Executive Director of 
the school’s Center 
on Drugs and Public 
Policy.  He is also 
an adjunct professor 
at the University 
of Maryland Carey 
School of Law where 
he teaches food and 
drug law.
What is your 
connection to the project from a professional 
perspective and why did you become involved in it? 
I had the pleasure of working with Diane 
Hoffmann, Jacques Ravel, and Virginia Rowthorn, 
among others, on an NIH probiotics project where 
we assessed the current regulatory structure 
surrounding probiotics and made recommendations 
for regulatory changes.
What will you bring that is unique to the project?
I am a pharmacist-attorney with a particular 
interest in food and drug law and have been 
practicing and conducting research in that area for 
many years.
Why do you think it’s important to study and make 
recommendations about microbiota transplantation at 
this point in history?
We are learning so much about the human 
microbiome and are just scratching the surface of 
possibilities in research and treatment.   Along with 
this comes federal and state law and regulation 
to protect those who are subjects of the treatment.  
Laws and regulations provide an approach 
that may indeed lead to proof of safety and 
effectiveness.
From your perspective, why is an interprofessional 
approach important to studying how microbiota 
transplantation should be regulated?
The answers to the questions we raise require an 
interdisciplinary approach, including assessments 
of treatment and procedures, basic scientific 
knowledge, and regulatory pathways to facilitate 
microbiota transplantation use.
What excites you about participating in the project?
It is a new area that is suddenly garnering a great 
deal of attention and I am honored to be part of 
the early phase of research.  And---I really enjoy 
working with my colleagues.
Dr. Mary-Claire Roghmann
Dr. Mary-Claire 
Roghmann is 
a Professor of 
Epidemiology & 
Public Health at 
the University of 
Maryland School 
of Medicine.  She 
is an infectious 
disease physician 
and clinical 
investigator whose 
research is focused 
on understanding 
bacterial and host 
determinants of S. 
aureus colonization, 
transmission and infection with the goal of developing 
better ways of preventing S. aureus infections, 
including those caused by antibiotic resistant strains 
such as MRSA. 
What is your connection to the project from a 
professional perspective and why did you become 
involved in it? 
I'm an infectious disease physician, 
epidemiologist and researcher interested 
in preventing infections. Manipulation of 
our microbiomes is a novel approach to this goal 
and microbiota transplantation is the first step 
in  this pathway.
What will you bring that is unique to the project?
My perspective as an infectious disease 
physician focuses on prevention. In addition as 
an epidemiologist, I bring a population-based 
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application that I, and most people performing the 
procedure, did not have. After an outcry from the 
medical community and patients, the FDA stopped 
enforcing this policy for patients with C. difficile 
infection not responding to conventional medical 
therapy.
While I appreciate that I can again offer my 
patients this procedure, I also appreciate the FDA’s 
desire to regulate microbiota transplantations. 
While altering a patient’s microbiome through 
fecal transplantation has been shown effective for 
Clostridium difficile infection, so far it has not 
proven effective for other conditions, has risks, and 
has been attempted for a myriad of conditions. I’m 
optimistic that the Working Group convened under 
this grant will help guide the FDA in a way that 
helps them strike a balance that allows for these 
procedures for conditions where they are proven 
to work, fosters rigorous scientific research, and 
maximizes patient safety.
What will you bring that is unique to the project?
As the only study team member that has performed 
microbiota transplantations on patients, I have a 
unique perspective on how they are performed and 
what regulatory issues have arisen at our local 
institution. I also have access to patients who can 
share their experiences.  
From your perspective, why is an interprofessional 
approach important to studying how microbiota 
transplantation should be regulated?
While seemingly simple, microbiota 
transplantation is a complex process, especially 
as currently performed. Is the donor microbiome 
a drug? A biologic product? A tissue? And how do 
you regulate a product for which the exact contents 
are unknown and change with every sample? By 
bringing together a broad team with expertise 
in the scientific, clinical, legal, and regulatory 
arenas, we hope to answer some of these important 
questions. 
Did you ever think you would be part of a project 
initiated at the law school and how has been working 
with lawyers been so far? 
Having several lawyers in the family, who believe 
they are correct ALL the time, I didn’t think I would 
be part of a project initiated at the law school, but 
so far it has been a lot of fun. 
perspective.
Why do you think it’s important to study and make 
recommendations about microbiota transplantation 
now (at this point in history)?
Now is the most important time to do this as we 
enter a new era when people think about how 
we could manipulate our microbiome to improve 
health.
Dr. Erik Von Rosenvinge
Erik Von Rosenvinge, 
MD, is an Associate 
Professor of Medicine 
in the Division of 
Gastroenterology 
& Hepatology at 
the University of 
Maryland School of 
Medicine and Chief 
of the GI Section 
at the Veterans 
Administration 
Maryland Health 
Care System.  Dr. 
Von Rosenvinge has 
performed fecal 
microbiota transplants on a number of his patients.
What is your connection to the project from a 
professional perspective and why did you become 
involved in it?
As a clinical gastroenterologist, I see patients 
with diseases associated with alterations in the 
gastrointestinal microbiome, such as intestinal 
infections, Crohn’s disease, and irritable bowel 
syndrome. One disease strongly linked to an 
abnormal microbiome is Clostridium difficile 
infection, a bacterial infection of the colon that 
typically begins after taking antibiotics and can 
cause severe diarrhea, toxic megacolon, and even 
death. This infection has a tendency to relapse after 
treatment and at times can be extremely difficult to 
cure.
After observing patients miserable from this 
disease, reading about ‘miracle cures’ from fecal 
transplantation, and reviewing the emerging 
scientific literature supporting the procedure, I 
began offering this procedure to my patients and 
have had great success. For a brief period the 
FDA prevented me from providing this procedure 
to my patients as they began requiring an IND 
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Diane Hoffmann Continues Work 
on Probiotics
At the end of Professor 
Hoffmann’s NIH grant 
to study the regulation of 
probiotics, Hoffmann and 
her colleagues completed an 
extensive white paper and 
published articles in sCieNCe 
and the JourNaL of food aNd 
drug Law based on the paper.  
Both written works described 
the recommendations 
that came from Working 
Group meetings.  Since the publication of the articles, 
Hoffmann has continued to speak and write about 
probiotics and other legal/ethical issues that came out of 
her study of the HMP and regulation of probiotics.
Articles
• Diane E. Hoffmann (with Jack Schwartz) “Stopping 
Deceptive Health Claims:  The Need for a Private 
Right of Action under Federal Law” (forthcoming in 
ameriCaN J. of Law & med.)
• Diane E. Hoffmann (with C.M. Fraser, F.B. Palumbo, 
J. Ravel, V. Rowthorn, &  J. Schwartz) “Probiotics: 
Achieving a Better Regulatory Fit,” 69 J. food & 
drug L. 237 (2014) 
• Diane E. Hoffmann (with C.M. Fraser, F.B. Palumbo, 
J. Ravel, K. Rothenberg, V. Rowthorn,&  J. Schwartz) 
“Probiotics: Finding the Right Regulatory Balance,” 
342 sCieNCe 314-315 (October 18, 2013)
• Diane E. Hoffmann (with Dennis Fortenberry 
& Jacques Ravel), “Do potential changes to the 
Common Rule adequately address new areas of 
research: A case study focusing on the Human 
Microbiome Project” 41 JourNaL of Law, mediCiNe & 
etHiCs 454 (Summer, 2013)
Lectures, Workshops & Speaking Engagements
• “Does Research on the Human Microbiome raise 
unique ethical or legal issues?” Institute of Medicine 
Annual Meeting, National Academy of Sciences 
Washington, D.C. (Oct. 19, 2014)
• Federal Regulation of Probiotics, Microbiota & 
Health Workshop, International Life Sciences 
Institute, Washington, D.C. (April 27, 2015)
• “Federal Regulation of Probiotics: An Analysis of the 
Existing Regulatory Framework” at FDA Symposium 
"Linking the Microbiome to Health, Safety, and 
Regulation," College Park, MD (September 29-30, 
2015)
Dr. Jacques Ravel
Dr. Jacques Ravel is 
Professor of Microbiology 
and Immunology at the 
University of Maryland 
School of Medicine and 
Associate Director for 
Genomics, Institute for 
Genome Sciences.  He 
is a national leader in 
microbial genomics and 
grantee of several HMP 
grants from NIH.
What is your connection to the project from a 
professional perspective and why did you become 
involved in it?
As a researcher working on understanding the role 
of the human microbiome in health and diseases, 
I worked with the team on a previous project 
evaluating the regulatory framework for probiotics 
in the US. My own work on the vaginal microbiome 
is connected to both the use of probiotics and 
microbiota transplants in order to restore vaginal 
health.
What will you bring that is unique to the project?
My expertise is in understanding the functional role 
of microbes in health and characterization of the 
human microbiome. These are important aspects to 
characterizing material to be transplanted and also 
evaluating the success of a transplant. 
From your perspective, why is an interprofessional 
approach important to studying how microbiota 
transplantation should be regulated?
Regulation involves many components from legal 
aspects, to information for consumers, to technical 
feasibilities, and, of course, regulation of product 
safety. To capture nuances associated with all these 
aspects, a multidisciplinary approach is essential. 
Did you ever think you would be part of a project 
initiated at the law school and how has been working 
with lawyers been so far? 
I never imagined myself working with faculty at the 
law school. When they approached me about the 
probiotics project, right away I saw the potential 
for a true collaboration, and my expectations were 
met.  It has been a great experience.  When they 
contacted me to contribute to this project, I never 
hesitated!
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It’s All Business to Some Health Law Graduates:
Innovative Ventures Created by Maryland Carey  
Health Law Alums
Although most of our health law students graduate 
and begin work in law firms or government positions, 
some entrepreneurial former students have started 
their own health-related businesses and all of them 
credit their law degree as critical to their success.  In 
this article, we feature three former students who went 
on to start their own businesses in three different, 
highly regulated areas of health and health care.
M. Jason Brooke ’10, CEO & General 
Counsel, Vasoptic Medical Inc.
Jason, a 2010 
graduate of the 
law school, was 
a scientist before 
he was a lawyer.  
Before studying 
law, Jason obtained 
a BS in Biological 
Resources 
Engineering at 
University of 
Maryland College 
Park and an MS 
from Johns Hopkins 
in Biomedical 
Engineering.  He 
then worked as 
a senior scientist 
developing implantable pacemakers and defibrillators 
for Boston Scientific Corporation.
As a law student, Jason externed at the Center for 
Devices & Radiological Health at FDA and served as 
Editor-in-Chief of the law school’s Journal of Health 
Care Law & Policy.  Upon graduation, he became 
an Associate at the law firm of Epstein Becker & 
Green (EBG) and, after several years of successful 
practice focused on the medical device and mobile 
health industries, Jason took the leap into the world of 
entrepreneurship, leveraging his experience in medical 
device development as a lawyer, biomedical engineer, 
and scientist.  His organization, Vasoptic Medical Inc., 
is commercializing technology that allows a doctor or 
scientist to non-invasively evaluate blood flow in the 
small blood vessels of any tissue that can be exposed 
to light. Vasoptic is currently working on a product 
line of retinal imagers that will allow scientists to use 
their technology for research purposes and doctors to 
diagnose and manage ophthalmic diseases that include 
diabetic retinopathy (the leading cause of blindness in 
American adults) and retinopathy of prematurity (one 
of the leading causes of blindness in children around 
the world). 
Since starting the business a little over three years 
ago, Brooke and his colleagues have made progress 
on both business and technology development fronts.  
Through close collaboration with the University of 
Maryland Medical Center and the Johns Hopkins 
University, the Vasoptic Team has been lucky enough 
to win over $1M in grants from the National Institutes 
of Health’s Small Business Innovative Research 
(SBIR) Program to develop the retinal imaging 
technology and to evaluate the use of their technology 
in surgical settings. They also recently received a 
$250,000 investment from the Abell Foundation, 
a non-profit dedicated to the enhancement of the 
quality of life in Maryland, with a particular focus on 
Baltimore. 
The company is now moving beyond the research 
stage toward clinical testing and deployment.  After 
consultation, FDA recently determined that their 
device is a “non-significant risk,” which means that 
Vasoptic can evaluate the retinal imager in a clinical 
setting without significant regulatory hurdles that 
often accompany the evaluation of investigational 
medical devices.  Brooke has big dreams for 
Vasoptic and hopes to see the company’s technology 
impact the optical health of people in the US and 
beyond.  In addition to moving ahead on the business 
front, Brooke and his colleagues are committed to 
being involved in the community - Team Vasoptic 
participates annually in the American Diabetes 
Association’s Walk to Stop Diabetes to help fundraise 
for the organization.
How did his legal training help get him where he 
is today?  According to Brooke, his legal training 
“has been critical to Vasoptic’s success thus far. 
The medical device industry, and healthcare more 
generally, is heavily regulated. Understanding FDA 
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regulations and CMS reimbursement requirements 
(not to mention corporate governance rules), gives 
us a leg up as an early stage company to ensure that 
we are developing our technology to be safe and 
effective to, ultimately, improve access to quality care 
at lower costs for the millions of people who need 
it most.” With such vision and passion for medical 
device development, it is not surprising that Jason was 
recently named one of Baltimore’s 40 Under 40 by the 
Baltimore Business Journal.           
Kylyn (Deary) Mead ’11, President and 
CEO, Go Docs Go
When Kylyn was just two years out of law school, 
she started her own “house call medicine” business 
called Go Docs Go.  She credits growing up in a 
family that owned a home health care business and 
a year as an attorney in the compliance department 
at the University of Michigan Health System as the 
foundation for her jump into business but, by any 
judge, she is a risk taker and it looks like her risk has 
paid off.  Kylyn now runs a business that employs 
40-45 employees and makes over 1500 house calls 
each month to patients in Michigan and Indiana.  Even 
more impressively, she entered a relatively niche 
area of health care delivery that is now starting to 
turn heads in Washington as a way to save costs for 
Medicare.  Congress endorsed a house call medicine 
demonstration project in the Affordable Care Act.  
What is a house call medicine?  Go Docs Go 
provides health care in the home for people who 
cannot travel to a health care facility because of age, 
illness or disability.  Go Docs Go uses physicians 
and nurse practitioners to perform the same services 
that a patient would receive in a traditional primary 
care physician office setting, including diagnosis, 
evaluation and treatment.  The company also helps 
coordinate medical care with other providers including 
physical therapy and hospice care.  For the most part, 
Go Docs Go is paid by patients’ Medicare Part B 
coverage.  While it is primarily a geriatric practice, 
Go Docs Go also has a number of younger veterans on 
their rolls.  
Kylyn’s biggest satisfaction from starting Go Docs 
Go has been her ability to provide for her patients 
beyond medical care.  Patients who cannot get to the 
hospital often have difficulty accessing social services 
as well and often seek care in emergency rooms for 
problems that could have been dealt with more easily 
– and more cheaply – in the home.  It’s for this reason 
that CMS is studying house call businesses via their 
Independence at Home program and considering how 
to reward businesses that save money for Medicare.  
At this point, the program is in the demonstration 
stage, but Kylyn hopes her company will be able to 
reap the benefits of the program in the future.
Kylyn’s legal training has been critical to her 
success as a business leader.  She notes that her 
industry is highly regulated and that her legal 
skills are critical during negotiations with the state, 
insurance carriers and Medicare.  Further, with all her 
employees, she has to understand contracts, human 
resources, and business law.  Even when she does use 
outside counsel, her legal training allows her to speak 
comfortably with other lawyers.  Overall, she credits 
her legal training with her ability to approach any 
problem with common sense.
Marcus Wang ’08, Co-Founder and  
General Manager, ZytoGen  
Global Genetics Institute
Although he 
did not receive 
the Health Law 
Certificate as a 
student, with the 
launch of ZytoGen 
Global Genetics 
Institute in 2013, 
Marcus Wang ’08 
has joined the Law 
& Health Care 
Program family at 
Maryland.
Wang partnered 
with two globally-
renowned pioneers 
in the field of 
infertility medicine to found ZytoGen, a molecular 
genetics laboratory providing Preimplantation Genetic 
Screening (PGS) to patients and clinics in the United 
States, Latin America, and Asia, through its CLIA-
certified laboratory in Baltimore County.  ZytoGen 
uses PGS to screen embryos for chromosomal 
abnormalities prior to implantation in the mother 
during the IVF process. The screening empowers 
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families to identify healthy embryos, lower the risk 
of miscarriage, and increase the likelihood of a 
successful pregnancy.
By optimizing conditions for single embryo transfer, 
ZytoGen also allows women the choice of avoiding 
the risks associated with multiple pregnancies, 
including selective reduction.  Known for its cutting 
edge technology and rapid turnaround time, ZytoGen 
continues to innovate, most recently by conducting 
the world’s first randomized clinical study on the 
efficiency of Next Generation Sequencing for PGS.
Despite his lifelong passion for business, Marcus 
grew up with a great deal of interest in, and respect 
for, the medical profession, which he sees as truly 
helping people. Both his parents are physicians, 
and his own interest in medicine spurred him to 
premed coursework at Harvard University as an 
undergraduate. Along with his interest in medicine, 
Marcus brings his international business experience 
to the operation of ZytoGen. Self-taught and fluent 
in both Mandarin and Cantonese Chinese, Marcus 
worked for the State of Maryland as an International 
Investment and Trade Specialist for China before 
coming to the law school and focusing on business 
law. Upon graduation, he practiced corporate law at 
the Manhattan office of DLA Piper before leveraging 
his business and legal skills to manage Under 
Armour’s expansion into the China market. 
While he still consults for U.S. businesses 
concerning China market entry, ZytoGen “completes 
a dream” for Marcus. As a boy, his parents would 
inspire him at the dinner table with stories of helping 
their patients. Today, he is humbled to help families 
fulfill their dreams. Recently, he spoke to a mother 
who brought a healthy baby to term after getting the 
green light from ZytoGen on a genetic screening.  
Hearing the baby’s happy babbling in the background 
of the call convinced Marcus that he is in the right 
field.
How does he use the law in his position as head of 
a health care company?  He credits law school with 
giving him a broad range of skills that have been 
critical to handling the legal and regulatory issues 
that are part of any start-up business, especially in the 
health arena.  In 2011, Mr. Wang was honored by the 
Maryland Daily Record, Maryland's premier business 
journal, as one of the “20 In Their 20s”, based on 
“professional accomplishment, civic involvement and 
impact of achievement.”  In October, Marcus will be 
speaking at the 30th anniversary of the L&HCP about 
the future of health law, specifically the intersection 
of law and biotechnology.  What does the future hold 
for Marcus?  It’s likely something that will continue to 
make us incredibly proud to call him an alum.
ACA regulations. HIPAA compliance. Insurance fraud and abuse.  
Do you tackle these challenges at work?
Go further.
Enhance your career with a new Master of Science in Law. A specialization in Health 
Care Law offers practical legal knowledge—and a competitive edge—to professionals 
working at the intersection of law and health care.
An affordable part-time, evening program at the 
University of Maryland, College Park.
http://www.law.umaryland.edu/msl
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The University of Maryland Francis King Carey School of Law recently launched a Business Fellowship 
Program to place law students and recent graduates in Baltimore-area businesses.  The new initiative is 
designed to help Maryland companies and institutions meet their business and legal needs while providing 
growth opportunities for the next generation of law and business leaders.  Three prominent health care 
institutions are inaugural partners in the program.   The University of Maryland Medical System (UMMS) 
is sponsoring a year-long postgraduate fellowship which was awarded to 2015 health law graduate 
Jaclyn Machometa.  FutureCare, which operates nursing and rehabilitation centers across the Baltimore/
Washington area, and LifeBridge Health, which owns a number of local hospitals, are participating in the 
10-week summer fellowship.  
Modeled after the judicial clerkship and internship experience, the Maryland Carey Law Business 
Fellowship Program offers fellows professional employment, mentoring, and a stipend with Baltimore-area 
businesses or organizations. Fellows will work in a corporate counsel’s office or in business operations.  
Given the number of health law students interested in these opportunities, other fellowships with health-
related organizations in Baltimore are currently under negotiation. 
In addition to teaching the popular Public Health Law Clinic, Professor Kathleen 
Hoke is also the Director of the Network for Public Health Law, Eastern Region and 
the Director of the Legal Resource Center for Public Health Policy at the University 
of Maryland Carey School of Law. The Network provides technical legal assistance 
to public health professionals and their attorneys at all levels of government, while 
the Legal Resource Center provides technical legal assistance to Maryland state and 
local health officials and organizations working on tobacco control and other public 
health issues.  For FY 2016, the organizations have been awarded grants in excess 
of $1 million to support their work.  Below is a brief summary of the activities and 
grants Professor Hoke and her staff are undertaking:
Legal Resource Center for Public Health
The Center will continue working under their 2001 grant from the Maryland Department of Health and Mental 
Hygiene (DHMH) to provide legal support to communities, community groups, employers, local governments, 
and State legislators and agencies interested in reducing the negative health consequences of tobacco use.  In 
addition, the Center will continue its injury prevention work that started in 2011 under a DHMH grant that is 
part of the Centers for Disease Control (CDC)’s Core Violence and Injury Prevention Program.
Network for Public Health Law, Eastern Region 
The Network was funded through a 2010 grant from the Robert Wood Johnson Foundation which has 
continued to fund the Network with a current grant through 2017.  The Network also has two grants from 
the CDC.  The first is in partnership with Change Lab Solutions and the National Alliance of State Pharmacy 
Associations to examine effective approaches to the development of collaborative practice agreements between 
physicians and pharmacists and to develop a case study on a state law expanding scope of practice laws for 
allied health professionals.  CDC also provided funds to the Network to study state efforts to address student 
athletes’ return to the classroom after sustaining a concussion, as well as to update an existing database of state 
youth sports-related traumatic brain injury laws.  Finally, the Network is working with funds provided by the 
Maryland Center of Excellence on Problem Gambling to support the Center’s policy and legislative work.
Professor Kathleen Hoke’s Public Health Efforts Draw  
$1 Million in Grant Funding
Law School’s New Business Fellowship Program Features  
Placements at Local Health Care Corporations
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Upcoming Conference:
Roundtable on Clinical Trials and Access to  
Essential Medicines in African Countries
On October 29-30, Law & Health Care Program faculty members Diane Hoffmann and Leslie Meltzer Henry 
along with Professor Peter Danchin, Director of Maryland Carey Law’s International and Comparative Law 
Program, are hosting a Roundtable on Clinical Trials and Access to Essential Medicines in African Countries. 
The meeting is being co-sponsored by the Faculty of Law at Chancellor College in Malawi and will bring 
together an international group of legal scholars and medical researchers to examine ethical and legal challenges 
to developing and distributing essential medicines in African countries.  The by-invitation-only meeting will 
focus on four topics:
•	 Access to essential medicines as a human right
•	 The law and ethics of clinical trials: what rules should govern clinical research in Africa?
•	 What do clinical researchers and sponsors owe to host communities?
•	 Legal regimes and obstacles: free trade, intellectual property, and access to medicine
In addition to Maryland Carey Law faculty, panelists include:
•	 Danwood Chirwa, professor, University of Cape Town Law Faculty
•	 Hilda Kaluwa Soko, law lecturer, University of Malawi Chancellor College of Law
•	 Lucie White, professor, Harvard Law School
•	 Victor Mwapasa, associate professor, University of Malawi College of Medicine
•	 Miriam Laufer, associate professor, University of Maryland School of Medicine
•	 Mark Barnes, partner, Ropes & Gray, LLP
•	 Joseph Mfutso-Bengo, professor of Bioethics and director of the Centre for Bioethics, University of
Malawi College of Medicine
•	 David Wendler, senior investigator and head of the Section on Research Ethics, NIH
•	 Seema Shah, faculty bioethicist, NIH
•	 Chikosa Banda, faculty of Law, University of Malawi Chancellor College of Law
•	 Lisa Forman, assistant professor, University of Toronto Law School
•	 Heinz Klug, professor and director, Global Legal Studies Center, University of Wisconsin
The roundtable is partially funded by the University of Maryland Baltimore Center for Global Education 
Initiatives which has supported collaboration between the Faculty of Law at Chancellor College in Malawi and 
Maryland Carey Law since 2010.  In 2013, L&HCP Director Diane Hoffmann and Maryland Carey Professor 
Peter Danchin traveled to Malawi to host a joint workshop on HIV/AIDS legal issues with Chancellor College 
faculty and students.  Following that visit, law faculty and students from both schools have made several trips 
across the Atlantic to learn from each other and share experiences in legal education.  This roundtable is the 
latest initiative of this unique collaborative relationship. 
The roundtable is also supported by the generous support of Alan & Nancy Eason; the Stuart Rome Lecture 
Fund; the Reuben Shiling Mental Health Law Fund; the Leonard C. Homer/Ober|Kaler Law and Health Care 
Fund; and the Dr. Richard H. Heller Fund   
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Professor Amanda Pustilnik and other L&HCP Faculty 
Blog on Pain Imaging and the Law
L&HCP Professor Amanda Pustilnik, a nationally recognized scholar on law 
and neuroscience, recently hosted a series of blog posts on the topic of pain 
imaging and the law for Harvard Law School’s Bill of Health blog.  The series 
was partly derived from three symposia Pustilnik has been involved with over 
the last 18 months.  The first was in April 2014 at the University of Maryland 
called “Imaging the Brain, Changing Minds: Chronic Pain Neuroimaging and 
the Law.” This meeting brought together pain neuroimaging researchers, legal 
decision-makers, and legal scholars for a cross-disciplinary dialog regarding 
the potential impact of neuroimaging on legal and cultural norms and led to a 
number of publications authored by Pustilnik (listed in the Faculty Highlights 
section, page 19).  
In April 2015, while Pustilnik was the inaugural Senior Fellow in Law & 
Applied Neuroscience at Harvard Law School and a faculty member at the 
Center for Law, Brain & Behavior (CLBB) at Massachusetts General Hospital, 
she participated in a conversation among experts called “Models of the Mind: 
How Neuroscience, Psychology, and the Law Collide.”  This meeting, which took place at Harvard Law School, 
convened experts in neuroscience, psychology, and the law to discuss three distinct models on the causes of 
human behavior and how these three models understand cause and effect, attribute blame, and think about 
rehabilitation.  Finally, in June 2015, Professor Pustilnik spoke at a public symposium sponsored by CLBB and 
Harvard’s Petrie-Flom Center called “Visible Solutions: How Neuroimaging Helps Law Re-envision Pain” that 
brought together the leading experts in neuroscience and law to wrestle with the critical question: what can, and 
should, the law do with what we know about pain and the brain?
To develop the series of blog posts, Pustilnik recruited L&HCP Professors Frank Pasquale and Diane Hoffmann 
to contribute along with other law faculty and pain researchers.  Hoffmann, who has written extensively about 
legal issues surrounding pain treatment, used the blog post to call for a federally-funded ELSI (ethical, legal, 
and social implications) program, similar to the ELSI program that accompanied the Human Genome Project, to 
study potential consequences of brain-based pain imaging.  L&HCP Professor Frank Pasquale discussed some of 
the political and sociological underpinnings of the impulse to measure and quantify pain and the potential risk of 
doing so to individuals with disabilities.  Pustilnik provided introductory and concluding posts.  The blogposts 
are available at the links below:
What Should the Future Look Like for Brain-Based Pain Detection? Three Eminent Scholars Weigh In, 
by Amanda C. Pustilnik 
http://blogs.law.harvard.edu/billofhealth/2015/07/31/what-should-the-future-look-like-for-brain-based-pain-
measurement-in-the-law-three-eminent-scholars-offer-their-views/
An ELSI Research Program for Pain Research: A Call to Action, by Diane Hoffmann 
http://blogs.law.harvard.edu/billofhealth/2015/07/31/an-elsi-program-for-pain-research-a-call-to-action
Of Algorithms, Algometry, and Others: Pain Measurement and the Quantification of Distrust, 
by Frank Pasquale 
http://blogs.law.harvard.edu/billofhealth/2015/07/31/of-algorithms-algometry-and-others-pain-measurement-the-
quantification-of-distrust/
Neuroimaging as Evidence of Pain: It's Time to Prepare, by Hank Greely 
http://blogs.law.harvard.edu/billofhealth/2015/07/31/neuroimaging-as-evidence-of-pain-its-time-to-prepare/
Other contributors to the series of blogposts include Karen Davis, Martha Farah, David Seminowicz, and Francis 
X. Shen. 
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Law & Health Care Program Celebrates Graduation  
of 30 Students
On May 14, Law & Health Care Program (L&HCP) 
faculty celebrated the graduation of 30 students 
who earned the health law certificate.  The breakfast 
celebration was held in the law school’s Westminster 
Hall with over 90 people in attendance, including 
family and friends of the graduates.  This year marks 
the 30th anniversary of the Law & Health Care 
Program and the 18th year that the program has 
been awarding certificates to students who complete 
the concentration in health law. This concentration 
requires that the students take 17 of their 85 law 
school credits in health law, participate in a health law 
clinic or externship, and write a scholarly paper on a 
health law topic.
As part of the celebration, faculty members came 
to the microphone to share the accomplishments of 
each of the students.  The comments they made, many 
of which included funny stories and fond memories, 
revealed an incredibly broad range of interests among 
the 2015 graduates.  Their enthusiasm and energy 
enriched the program and inspired everyone in 
attendance.  Below we highlight five of the students 
who received the health law certificate this year.  
Nikita M. Floore 
Nikita Floore came to the law school with a BA 
in English and MS in Rehabilitation Counseling 
from Southern Illinois University.  Prior to starting 
her law studies, she held a number of vocational 
rehabilitation positions at the U.S. Department of 
Veterans Affairs and the Tennessee Department of 
Human Services, including her final position as a 
Health System Specialist at the VA in Washington, 
DC where she managed a $31 million operational 
budget for the Office of Primary Care.  Her work in 
rehabilitation led Nikita to the L&HCP and ensured 
that she was a student leader while she was here.  
Nikita was a Leadership Scholar and served as an 
Admissions Ambassador for the Office of Admissions.  
She was also on the board of the Student Health Law 
Organization (SHLO) and participated in the Maryland 
Carey Service Corps trip to the Delta Region of 
Mississippi.  She was able to travel back to Southern 
Illinois University as a participant in the Health 
Law Moot Court Competition sponsored by SIU’s 
law school.  Nikita spent her second summer at the 
American Health Lawyers Association as a Diversity 
Fellow and was very active while in law school with 
the Black Law Students Association.  Professor Frank 
Pasquale who had Nikita for Health Care Law & 
Policy and Administrative Law told the audience at 
the graduation breakfast, “Nikita has been a leader in 
the health law program. She has brought extraordinary 
real-world experience to both my classes.  I will 
2015 Health Law Certificate Graduates and L&HCP Faculty
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always remember Nikita as one of the most inspiring, 
dynamic, insightful, and professional students I’ve 
ever known.”  Nikita now works at FDA as Regulatory 
Counsel in the Center for Tobacco Products where 
she is responsible for assisting in the resolution of 
compliance issues concerning the application of the 
Tobacco Control Act.  
Sherrie R. Bailey in the Circuit Court for Baltimore 
County.
Ethan Han 
Ethan came to Maryland Carey Law with a BA in 
Political Science from University of Michigan which 
clearly instilled in him the networking skills of a 
seasoned politician.  Ethan may have set a record 
for the number of health law-related internships, 
externships and experiences he had as a student at the 
law school.  He externed at a medical-legal partnership 
called Project HEAL at Baltimore’s Kennedy Krieger 
Institute and at the Pacific Islander American Health 
Forum in Bethesda, Maryland.  He interned (not for 
credit) at Dimensions Healthcare System and at the 
American Podiatric Medical Association.  He was 
also a research assistant for L&HCP faculty member 
Deborah Weimer, a student attorney in the Public 
Health Law Clinic, and a member of the Executive 
Board of the Student Health Law Organization 
(SHLO).  Finally, he found time to join Sean 
Gugerty as a teammate for the Loyola University 
Chicago School of Law’s Health Law Transactional 
Competition where the team came in third place. 
Virginia Rowthorn, Managing Director of the L&HCP, 
said of Ethan, “There has not been a single SHLO 
event or initiative that Ethan didn’t help organize 
(or at least it seemed that way).  He will be missed 
tremendously.”  This year Ethan is clerking with Judge 
Alfred Nance of the Maryland Circuit Court. 
Professsor Leslie Meltzer Henry, 2015 Graduate Amy 
Dobrzynzki and L&HCP Director Diane Hoffmann  
(from l to r)
Sean Gugerty
Sean Gugerty established himself as a leader in the 
health law program from the minute he stepped on 
campus.  In his first semester, when L&HCP Director 
Diane Hoffmann asked for student volunteers, 
Sean took part in an initiative with the School of 
Medicine in which students from both schools were 
asked to work together on an end-of-life scenario 
and brainstorm about medical and legal solutions.  
His willingness to take this on in his first year is 
absolutely consistent with the type of student Sean 
was - dedicated, curious, bright, and helpful.  There 
was rarely a time that L&HCP faculty reached out to 
students for help that the first response did not come 
from Sean.  He was student chair for the law school’s 
Health Law Regulatory and Compliance Competition, 
on the Executive Committee of the Moot Court Board, 
and Notes & Comments Editor for the Journal of 
Health Care Law & Policy.  He also represented the 
law school at the Loyola University Chicago School 
of Law’s Health Law Transactional Competition.  At 
the celebration, Professor Kathleen Hoke said to the 
assembled group, “Sean was a student in my Public 
Health Law Clinic, so we spent quite a lot of time 
together over the course of the semester. And it was all 
to my benefit! Sean is not only bright, hard-working 
and impressively professional; he is also genuinely 
nice and engaging.” Sean is now clerking for Judge 
2015 Graduate Kelsey-Anne Fung with her parents  
and Professor Frank Pasquale (from r to l)
Jaclyn A. Machometa 
Jaclyn was recently selected to spend the year as 
a Postgraduate Business Fellow at the University 
of Maryland Medical System in the Office of the 
Legal Counsel (see box, page 10).  Jaclyn’s law 
school resume made this honor a natural fit.  Jaclyn 
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was the Managing Editor of the Maryland Law 
Journal of Race, Religion, Gender and Class, Vice 
President of the Women’s Bar Association, awarded 
a Maryland Public Interest Law Project grant, and, 
upon graduation, winner of the Joseph Bernstein 
Award for written journal submissions for an article 
titled, “Round up the Usual Suspexts: Advocating for 
Leniency on Consensual, Teenage Sext Offenders” ( 
md. J. raCe, reLigioN, geNder & CLass (Fall 2014)).  
She also externed at the Johns Hopkins Hospital 
System and at University of Maryland Medical System 
while she was a student.  But these accomplishments 
and activities do not reflect the passion for social 
justice that Jaclyn was known for.  Some of her 
most important experiences during law school were 
her time as a student Attorney in the Civil Rights of 
Persons with Disabilities Clinic and as a Fellow at 
Project HEAL (Health, Education, Advocacy, and 
Law) a medical-legal partnership supported by the 
Maryland Volunteer Lawyers Service (MVLS) and the 
Johns Hopkins Children’s Center.  Jaclyn is committed 
to working for social justice and plans to find a job 
in this field when her Fellowship ends.  As her clinic 
professor Marc Charmatz noted, “We’re very sad 
she’s graduating, but thrilled to see the health law field 
receive such a competent and committed advocate.”
Neha Patel 
Neha Patel is a truly gifted student of both pharmacy 
and law. She graduated with a PharmD and JD in 
May and just started as an Associate at Arnold & 
Porter in their FDA and Healthcare practice.  Neha 
excelled in both schools.  At the School of Law, she 
was active in SHLO and represented the law school 
at our own Health Law Regulatory and Compliance 
Competition.  At the School of Pharmacy, she won 
2015 Graduates Ashley Woolard, Theresa Mahfood, 
Oyinladun Adeleye and Nikita Floore (from l to r)
3rd Place in the University of Maryland's Center of 
Excellence in Regulatory Science and Innovation 
Competition, was on the Dean’s List (top 3%), and 
won the Student Government Association Leadership 
Award among other accolades.  Although she took 
classes simultaneously at both schools, she was 
able to fully immerse herself as a scholar in both 
communities.  In addition to interning twice in the 
FDA Commissioner’s office (once in the Office of 
Policy and Planning and once in the office of Health 
and Constituent Affairs), she was a student research 
assistant in the School of Pharmacy’s Center on Drugs 
and Public Policy. Neha wrote a paper for Professor 
Frank Pasquale on drug-drug interaction alerts that 
was, according to him, “a truly thoughtful, important 
contribution to the field. It offered a smart, sensible 
way of tiering alerts so as to reduce physician and 
pharmacist ‘alarm fatigue’ while simultaneously 
anticipating liability concerns.”  He also predicted that 
“Neha is going to be a leader in the field of health law 
and policy, bringing deep expertise in both law and 
science to the most pressing problems.”
Oyinladun O. Adeleye
Lindsay Erin Bramble
Evelyn Castillo
Amy Dobrzynski
Benjamin L. Eastman
Debra Zweier Ehudin
Nikita M. Floore
Kelsey-Anne C. Fung
Andrew Geltman
Sean Gugerty
 
 
Ethan Han
Andrés Heiney-González
Grant Herdrich
Lindsey E. Imus
Suela John
Connie Lee
Lindsay Lowe
Jaclyn A. Machometa
Theresa Mahfood
Neha Patel
 
 
Nicholas Rodriguez
Jason Alan Ruben
Mellissa Sager
Samantha Sherman
Darci Marie Smith
Michael N. Tennison
Trevonne Victoria Walford
Andrew Weissenberg
Ashley Woolard
2015 health law certificate recipients 
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30th Anniversary Celebration of the  
Law & Health Care Program
Thursday, October 15, 2015 
4:00 p.m.
University of Maryland Carey School of Law 
Join program alumni, faculty, friends, and staff for an evening 
of learning and reminiscing!
Panels moderated by our renowned faculty will examine the past, present, and future of 
health law with experts including:
•	 Joanne Pollak ‘76, senior vice president, general counsel and chief of staff, Johns 
Hopkins Medicine
•	 Sanford Teplitzky, principal, Ober|Kaler
•	 Jack Schwartz, adjunct professor and former Maryland assistant attorney general and 
director of Health Policy Development 
•	 Carolyn Quattrocki, executive director, Maryland Health Benefit Exchange
•	 Peter Parvis ‘77, principal, Miles & Stockbridge 
•	 Marcus Wang ‘08, general manager and co-founder, ZytoGen, LLC
•	 David Cade ‘85, CEO, American Health Lawyers Association
The evening will also include a staged reading and facilitated discussion of “Bioethics 
in Play: The Drama of DNA,” a play co-authored by Professor Karen Rothenberg that 
probes the ethical and legal dimensions of emerging medical technologies.
To register, please go to:
http://maryland-carey-law.ticketleap.com/healthcare30/ 
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Law & Health Care Program  
Faculty Highlights
Richard Boldt
Publications
“Perspectives on Outpatient Commitment,” 49 New 
eNgLaNd Law review 39-80 (2014)
“The ‘Voluntary’ Inpatient Treatment of Adults 
Under Guardianship,” 60 viLLaNova Law review 
1-52 (2015)
Presentations and Speaking Engagements
“Restorative Justice and Sentencing Alternatives, 
Advanced Topics in Sentencing,”  Judicial Institute 
of Maryland (March 2015)
Sara Gold
Presentations and Speaking Engagements
Presenter HIV Criminalization: Preparing the Future 
Program, JACQUES Initiative of the Institute of 
Human Virology at the University of Maryland 
School of Medicine (March 31, 2015)
Honors/Appointments
Member, Baltimore City HIV Planning Group and 
Commission, Baltimore, Maryland (Commission 
sworn in by Mayor Stephanie Rawlings-Blake on 
November 5, 2014) 
Michael Greenberger
Presentations/Panel Facilitations
“Legal Preparedness after Hurricane Sandy,” Public 
Health Law Conference, Atlanta, Georgia (October 
16, 2014)
“Legal Aspects of Mass Immunizations and Routine 
Vaccination,” Center for Vaccine Development 
Vaccinology Course, University of Maryland School 
of Medicine (February 18, 2015)
“Legal Issues Arising from Ebola and other Global 
Pandemic Diseases,”  New York Bar Association’s 
Council on International Affairs, New York N.Y. 
(February 24, 2015)
Honors/Appointments
Appointment to the National Academies of Science, 
Engineering, and Medicine’s Committee on Science, 
Technology, and the Law
Leslie Meltzer Henry
Publications
“Just Compensation: A No-Fault Proposal for 
Research-Related Injuries,” J.L. & BiosCieNCes  
(with Megan E. Larkin and Elizabeth R. Pike) 
(2015)
“Respect and Dignity: A Conceptual Model for 
Patients in the Intensive Care Unit,” 5 Narrative 
iNquiry BioetHiCs (Special Issue) 5A (with Cynda 
Rushton, Mary Catherine Beach, and Ruth Faden) 
(2015)
“Linking Patient Registries and Biorepositories” 
in Agency for Healthcare Research and Quality, 
Registries for Evaluating Patient Outcomes: A 
User’s Guide  (with Benjamin Greenberg and Helen 
Moore) (4th ed., forthcoming 2015 )
Presentations/Panel Facilitations
“The Ethics of Digital Experimentation,” The 
Conference on Digital Experimentation, MIT, 
Boston, MA (October 10, 2014)
“The Law and Ethics of Digital Experimentation,” 
American Health Lawyers Association and Drexel 
School of Law, Philadelphia, PA (October 23, 2014)
“Just Compensation: A No-Fault Proposal for 
Research-Related Injuries,” Trans-NIH Bioethics 
Advisory Committee (T-NBC), National Institutes of 
Health, Bethesda, MD (January 20, 2015)
“Minor Consent: A Survey of State Laws,” at 
conference “Examining Mature Minor Consent for 
Participation in HIV Prevention Research,” co-
sponsored by the National Institute of Allergy and 
Infectious Disease (NIAID), National Institute of 
Mental Health (NIMH), and National Institute of 
Child Health and Development (NICHD), Rockville, 
MD (June 24, 2015)
Honors/Appointments
Promoted to full Professor of Law with tenure 
(effective July 1, 2015)
Diane Hoffmann
Publications
“Laying the Foundation for an Interprofessional, 
Comparative Health Law Clinic,” (with C. Banda 
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and K. Amuli) 42 J. Law, med. & etHiCs 392 (Fall 
2014)
Report to the Maryland Health Services Cost 
Review Commission on Defensive Medicine, (with 
B. Herring) (February 15, 2015)
“Increasing Access to Dental and Medical Care by 
Allowing Greater Flexibility in Scope of Practice,” 
(with R. Manski and V. Rowthorn) 105 aJPH 9 
(September 2015)
“Stopping Deceptive Health Claims:  The Need for 
a Private Right of Action under Federal Law” (with 
Jack Schwartz) (forthcoming in ameriCaN J. of Law 
& med.) 
Presentations/Panel Facilitations
“Does Research on the Human Microbiome raise 
unique ethical or legal issues?” Institute of Medicine 
Annual Meeting, National Academy of Sciences 
Washington, D.C. (Oct. 19, 2014).
“Religious, Medical, and Legal Perspectives on End 
of Life Issues,” Panelist, University of Maryland 
Baltimore Interprofessional Conference, Baltimore, 
MD (Nov. 10, 2014)
“How will the practice of defensive medicine affect 
the ability of the Maryland Health Services Cost 
Review Commission to implement its new global 
budget reimbursement model?” Maryland Health 
Services Cost Review Commission, Baltimore, MD 
(Jan. 9, 2015 and March 11, 2015)
Federal Regulation of Probiotics, Microbiota & 
Health Workshop, International Life Sciences 
Institute, Washington, D.C. (April 27, 2015)
“Medically Ineffective Treatment in Maryland,” 
Prince George’s Hospital Center CME Lecture, 
Cheverly, MD (April 30, 2015)
“Federal Regulation of Probiotics: An Analysis 
of the Existing Regulatory Framework” at FDA 
Symposium, "Linking the Microbiome to Health, 
Safety, and Regulation," College Park, MD 
(September 29-30, 2015)
Honors/Appointments/Grants
Grant to study the practice of defensive medicine 
for the Maryland Health Services Cost Review 
Commission (Jan. 2015)
Awarded two-year NIH Grant (ELSI grant 
from NIAID), “Microbiota Transplantation: 
Recommendations for a Regulatory Framework” 
(June 2015)
Kathleen Hoke
Publications
“Guidelines for Avoiding Pitfalls when Drafting 
Juvenile Curfew Laws: A Legal Analysis,” 8 st. 
Louis u. JourNaL of HeaLtH Law & PoLiCy 301 
(with Elyse R. Grossman) (2015)
Presentations/Panel Facilitations
“Emerging Issues in Public Health Law” at National 
Public Health Law Conference, Atlanta, GA 
(October 17, 2014)
 “The State’s Role in Tobacco Regulation” at the 
Food and Drug Law Institute’s Annual Conference, 
Washington, DC (April 21, 2015) 
 
Frank Pasquale
Publications
“Privacy, Autonomy, and Internet Platforms,” 
in PrivaCy iN tHe moderN age (edited by Marc 
Rotenberg, Jeramie Scott, and Julie Hurwitz, 2015) 
(discussing the Facebook emotional manipulation 
experiment)
“Promoting Innovation While Preventing 
Discrimination: Policy Goals for the Scored 
Society,” 89 wasHiNgtoN Law review 1413 (2015) 
(with Danielle Keats Citron)
“The Algorithmic Self,” 17(1) HedgeHog review 23 
(2015)
Presentations/Panel Facilitations
Mitchell Lecture: “Who Rules Big Data?,” SUNY 
Buffalo Law School (March 27, 2015)
Commenter on two papers on law and synthetic 
biology and law and genetics at Yale Law School’s 
Innovation Beyond IP conference (March 28, 2015)
Multiple book talks re: tHe BLaCk Box soCiety 
at Harvard Law School, the Rochester Institute 
of Technology, Georgetown University Center 
for Privacy and Technology, and the Columbia 
University Division of Social Science 
Honors
Named Editor-in-Chief of Laws, a peer-reviewed 
journal of legal theory
Named, Member of the Advisory Board, JourNaL of 
LegaL eduCatioN 
Named, Member of the Advisory Board, the Data 
Competition Institute. 
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Amanda Pustilnik
Publications
“Imaging Brains, Changing Minds: How 
Neuroimaging Can Transform the Law’s Approach 
to Pain,” 66 aLa. L. rev. 1099 (2015) 
19 J. HeaLtH Care L. & PoL’y 1 (2015) (symposium 
issue) 
•	 “Legal and Neuroscientific Perspectives on 
Chronic Pain”
•	 “‘Excess Pain’ and the Reasonable Suffering 
Standard in Disability Law”
•	 “Chronic Pain, “Psychogenic” Pain, and 
Emotion in Tort and Disability”
•	 “Translational Expectations & Issues: Making 
it Work in Practice”
“Let’s Stamp Out Perversion: Against the Abuse of 
Civil Commitment for the Post-Carceral Detention 
of “Sexually Violent Predators” blog post on Cato 
uNBouNd (Cato Institute Blog) (June 9, 2015) 
Karen Rothenberg
Publications
“The Ethical, Legal, and Social Implications 
Program of the National Human Genome Research 
Institute: Reflections on an Ongoing Experiment” 
(with J. McEwen, J. Boyer, K. Sun, N. Lockhart and 
M. Guyer), 15 aNNuaL rev. geNomiCs Hum. geNet. 
481 (September 2014)
tHe drama of dNa: Narrative geNomiCs, (with 
L.W. Bush) Oxford Univ. Press (2014)
“Finding Fault? Exploring Legal Duties to Return 
Incidental Findings in Genomics Research,” (with 
E.R. Pike and B.E. Berkman), 102 georgetowN L.J. 
795 (2014) 
“Setting the Stage: Enhancing Understanding of 
Bioethical Challenges with Theatre,” 11 iNd. HeaLtH 
L. rev. 1 (2014)
Presentations/Panel Facilitations
Presenter and Facilitator (with L. Bush), “Bioethics 
in Play: The Drama of DNA”, Berman Institute 
of Bioethics Intensive, Johns Hopkins University, 
Baltimore, MD  (June 4, 2015)
Presenter, “All the World’s a Stage: Exploring 
Bioethical Challenges with Theatre”, Cultural 
Programs of the National Academy of Sciences, 
Performing Science, DC Art Science Evening 
Rendezvous, Washington, DC (June 18, 2015)
Presenter and Facilitator (with L. Bush), “Clinical 
Genomics in Play: The Drama of DNA”, Festival of 
Genomics, Frontline Genomics, Boston, MA (June 
23, 2015)
Invited participant, Workshops on Privacy and Trust, 
Precision Medicine Initiative, White House Office 
of Science and Technology Policy, (March and July 
2015) 
Virginia Rowthorn
Publications
“All Together Now: Developing a Team Skills 
Competency Domain for Global Health Education,” 
42 JourNaL of Law, mediCiNe & etHiCs 550 (2015) 
(with Jody Olsen). 
“Identifying Interprofessional Global Health 
Competencies for 21st Century Health 
Professionals,” 81 aNNaLs of gLoBaL HeaLth 239 
(2015) (with others).
“Putting the Pieces Together:  Creating and 
Implementing an Interprofessional Global Health 
Grant Program,” HeaLtH Care: tHe JourNaL of 
deLivery sCieNCe aNd iNNovatioN (Global Health 
Issue) (with Jody Olsen) (forthcoming Winter 2015) 
Ellen Weber
Presentations
“Licensure Standards for Opioid Treatment 
Programs and Compliance with the Americans With 
Disabilities Act,” Testimony before the Maryland 
Senate Finance Committee and House Heath and 
Government Operations Committee (Feb. 18 and 
March 31, 2015)
“Mental Health Parity and Addiction Equity Act,” 
Testimony before the Maryland Senate Finance 
Committee and House Health and Government 
Operations Committee (Feb. 25 and 26, 2015) 
Honors/Appointments/Grants
Weber’s Drug Policy and Public Health Solutions 
Clinic was also awarded a third two-year grant from 
the Open Society Institute-Baltimore for $280,000 
to help establish a medical-legal partnership with 
two drug treatment programs to address insurance 
coverage issues and access to health services. 
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Comments and letters should be 
forwarded to the above address.
Support the Law & Health Care Program
The Law & Health Care Program has hosted a number of hallmark meetings and roundtables to bring 
together health care practitioners, legal academics, medical experts, scientists, and policymakers to 
examine cutting-edge issues in health policy, law, or ethics. Over the next 30 years, we hope to count you 
as a partner in this effort. We plan to build on the stellar foundation we have created as health law educators 
to keep asking questions and pushing the field of health law forward. In order to do this, we are asking for 
your support. Every contribution helps our program achieve its goals.
There are two ways to give to the Law & Health Care Program:
~ Online at http://www.law.umaryland.edu/give/healthlaw 
~ Mail, by sending a check made payable to: UMBF, Inc./ Law & Health Care 
to 620 West Lexington Street, 2nd Floor, Baltimore, MD 21201
Funds for the Law & Health Care Program are administered by the University of Maryland, Baltimore Foundation, Inc.
